Keyphrases
Mayo Clinic
100%
Hepatobiliary
100%
Hepatobiliary Cancer
100%
Cholangiocarcinoma
100%
Clinical Trials
66%
Viroimmunotherapy
66%
Yes-associated Protein 1 (YAP1)
66%
Standard of Care
66%
Virotherapy
66%
Enhancement Program
33%
Career Enhancement
33%
Chemotherapy Sensitivity
33%
Cancer Biology
33%
Early Prognosis
33%
Microenvironment
33%
Clinical Efficacy
33%
Carcinoma
33%
Liver Cancer
33%
Precision Medicine
33%
Cancer Mortality
33%
Oncolytic Virus
33%
Fibrolamellar
33%
Chimeric Antigen Receptor T Cells (CAR-T)
33%
Pediatric
33%
Early Detection
33%
Urinary Biomarkers
33%
Early Diagnosis
33%
Cell Viability
33%
Comprehensive Cancer Center
33%
Transcriptional Enhanced Associate Domain
33%
Patient Responsiveness
33%
First-in-class
33%
Immunotherapeutics
33%
Computational Biology
33%
Translational Science
33%
Chemical Genomics
33%
Immune-suppressive
33%
Older Adults
33%
Therapeutic Response
33%
Functional Approach
33%
New Combination
33%
Oncogenic Signaling
33%
Clinical Prognosis
33%
Thera
33%
Biliary Tree
33%
Drug Repurposing
33%
Patient-centered
33%
Blood Biomarkers
33%
Tumor Cells
33%
Cancer Causes
33%
Sleeping Beauty
33%
Novel Inhibitors
33%
Tumor Burden
33%
Ongoing Support
33%
Translational Research Programs
33%
Diagnosis Treatment
33%
Patients with Cancer
33%
Developmental Research
33%
Liver
33%
Medicine and Dentistry
Hepatobiliary Cancer
100%
Cholangiocarcinoma
100%
Virotherapy
66%
Clinical Trial
66%
Malignant Neoplasm
33%
Translational Research
33%
Immunotherapy
33%
Pediatrics
33%
Drug Repositioning
33%
Cancer Pathobiology
33%
Cancer Mortality
33%
Tumor Cell
33%
Personalized Medicine
33%
Oncolytic Virus
33%
Carcinoma
33%
Treatment Response
33%
Biological Marker
33%
Chimeric Antigen Receptor T-Cell
33%
Neoplasm
33%
Cell Viability
33%
Carcinogenesis
33%
Pharmacology, Toxicology and Pharmaceutical Science
Bile Duct Carcinoma
100%
Clinical Trial
66%
Virotherapy
66%
Neoplasm
66%
Malignant Neoplasm
33%
Oncolytic Virus
33%
Carcinoma
33%
Cancer Mortality
33%
Drug Repositioning
33%
Immunotherapy
33%
Cell Viability
33%
Biological Marker
33%
Carcinogenesis
33%